Impact of intermediate to high doses of methylprednisolone on mortality rate in patients with COVID-19 pneumonia-induced severe systemic inflammation.

Mónica Climente-Martí Oreto Ruiz-Millo Ian López-CruzÁngel Atienza-GarcíaEva Martínez-MoragónEmilio Garijo-GómezMaría Luisa López-GrimaRafael Zaragoza-CrespoJuan Vicente Llau-PitarchDaniel Bautista-RenteroJosé Miguel Nogueira-CoitoTomás Ripollés-GonzálezMaría Antonia Marco-ArtalRamón Romero-SerranoFrancisco Dolz-SinisterraRosario López-Estudillonull null

Published in: International journal of clinical practice (2021)

Intermediate to high doses of methylprednisolone, initiated between 5 and 12 days after symptom onset, was associated with a significant reduction in 28-day all-cause mortality in patients with COVID-19 pneumonia and ≥3 o ≥ 4 altered IB, independently of the need of respiratory support.

Keyphrases

high dose
high glucose
drug induced
cardiovascular events
risk factors
low dose
type diabetes
community acquired pneumonia
oxidative stress
mechanical ventilation